Open Nav

Azitra, Inc.

Secure investor interest in leading B series investment

  • Date:Wednesday, October 17
  • Time:3:30 PM - 3:45 PM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Azitra Inc. (Azitra) was established in 2014 to leverage the promise of the microbiome to address both skin disease (e.g. eczema, netherton’s, etc.) and adverse skin conditions (e.g. flaky, dry, rough skin). Skin disease and skin problems afflict millions of individuals worldwide. The Company believes that the microbiome holds the key to addressing these challenges and has assembled an experienced team of drug development specialists, microbiologists, biochemists, dermatologists and experts in industrial microbiology to meet its goals. Azitra has robust technical platform and 3 products entering clinical development in 2019.
  • Company Website:www.azitrainc.com
  • Company HQ City:Farmington, CT
  • Company HQ Country:United States
  • Company HQ State:Connecticut              
  • CEO/Top Company Official:Richard Andrews
  • Year Founded:2014
  • Main Therapeutic Focus:Dermatology
  • Lead Product in Development :AZT-01 for the treatment of Atopic Dermatitis
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :3
  • Additional Information/Comments:Azitra, Inc. is a preclinical stage biotechnology company combining the power of the microbiome with cutting-edge genetic engineering to treat skin disease. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its consumer health and pharmaceutical programs to treat atopic dermatitis, rough, dry skin and targeted orphan indications (such as Netherton's). The Company is moving into its first in human clinical trials this fall, for its personal car product and will be initiating Phase 1/2 IND studies for its eczema and netherton's programs in 2019. Azitra has an extraordinary IP position covering the use of the microbiome in disease treatment and has established full GMP manufacturing and formulation for its products. The company has an excellent SAB and significant group of investors committed to supporting the Company through it's clinical programs coming in 2019.
  • Previous and Current Investors:Bios Partners, Thiel Foundation, KdT Ventures, Connecticut Innovations
  • Size of Last Investment Round:$2.1
  • Total Amount Raised to Date, In All Rounds:$5.4M
Back